PMID- 33327335
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210302
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Comparison of noninvasive scoring systems for the prediction of nonalcoholic 
      fatty liver disease in metabolic syndrome patients.
PG  - e23619
LID - 10.1097/MD.0000000000023619 [doi]
LID - e23619
AB  - Over half of metabolic syndrome (MetS) patients have nonalcoholic fatty liver 
      disease (NAFLD). To prevent its complications, standard routine screening is 
      required, but the human-resource and budgetary implications need to be taken into 
      consideration. This study compared the performances of 4 noninvasive scoring 
      systems in predicting NAFLD in MetS patients. They were the fatty liver index, 
      hepatic steatosis index, lipid accumulation product index, and nonalcoholic fatty 
      liver disease in metabolic syndrome patients scoring system (NAFLD-MS).Scores 
      were determined for 499 MetS patients, including 249 patients in a type 2 
      diabetes mellitus (T2DM) subgroup. Ultrasonography was used to diagnose NAFLD. 
      The accuracies and performance of the scoring systems were analyzed using 
      published cutoff values, and comparisons were made of their areas under receiver 
      operating characteristic curves, sensitivities, specificities, positive and 
      negative predictive values, and likelihood ratios.NAFLD was detected in 68% of 
      the MetS patients and 77% of the MetS patients with T2DM. According to the areas 
      under receiver operating characteristic curves, fatty liver index and hepatic 
      steatosis index provided better performances in predicting NAFLD. NAFLD-MS 
      provided the highest specificity of 99% among the MetS patients as a whole, and 
      it provided even better accuracy with similar performance when applied to the 
      subgroup of MetS patients with T2DM. The maximum cost avoidance from unnecessary 
      ultrasonography was also reported by using NAFLD-MS. In terms of simplicity and 
      ease of calculation, the lipid accumulation product index and NAFLD-MS are 
      preferred.All 4 scoring systems proved to be acceptable for predicting NAFLD 
      among MetS and T2DM patients in settings where the availability of 
      ultrasonography is limited. NAFLD-MS provided the highest specificity and cost 
      avoidance, and it is simple to use. All 4 systems can help clinicians decide 
      further investigations.
FAU - Saokaew, Surasak
AU  - Saokaew S
AUID- ORCID: 0000-0002-1382-0660
AD  - Center of Health Outcomes Research and Therapeutic Safety (Cohorts).
AD  - Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN).
AD  - Unit of Excellence on Herbal Medicine.
AD  - Division of Pharmacy Practice, Department of Pharmaceutical Care, School of 
      Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
AD  - Biofunctional Molecule Exploratory Research Group, Biomedicine Research 
      Advancement Centre, School of Pharmacy.
AD  - Novel Bacteria and Drug Discovery Research Group, Microbiome and Bioresource 
      Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash 
      University Malaysia, Bandar Sunway, Selangor Darul Ehsan, Malaysia.
FAU - Kositamongkol, Chayanis
AU  - Kositamongkol C
AUID- ORCID: 0000-0001-7182-0733
AD  - Division of Ambulatory Medicine.
FAU - Charatcharoenwitthaya, Phunchai
AU  - Charatcharoenwitthaya P
AUID- ORCID: 0000-0002-8334-0267
AD  - Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Srivanichakorn, Weerachai
AU  - Srivanichakorn W
AUID- ORCID: 0000-0001-9581-7117
AD  - Division of Ambulatory Medicine.
FAU - Washirasaksiri, Chaiwat
AU  - Washirasaksiri C
AUID- ORCID: 0000-0002-3078-0541
AD  - Division of Ambulatory Medicine.
FAU - Chaiyakunapruk, Nathorn
AU  - Chaiyakunapruk N
AUID- ORCID: 0000-0003-4572-8794
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, UT, USA.
FAU - Phisalprapa, Pochamana
AU  - Phisalprapa P
AUID- ORCID: 0000-0003-1995-4405
AD  - Division of Ambulatory Medicine.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Diabetes Mellitus, Type 2
MH  - Female
MH  - Humans
MH  - *Liver Function Tests
MH  - Male
MH  - *Metabolic Syndrome
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*diagnosis/physiopathology
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
PMC - PMC7738027
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2020/12/18 06:00
MHDA- 2021/01/07 06:00
PMCR- 2020/12/11
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/12/11 00:00 [pmc-release]
AID - 00005792-202012110-00116 [pii]
AID - MD-D-20-07876 [pii]
AID - 10.1097/MD.0000000000023619 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23619. doi: 
      10.1097/MD.0000000000023619.